Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

NCT05162365 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.

NCT NCT05162365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 6, 2022
Completion date
November 18, 2022
Enrollment
248 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19